Thermo Fisher Scientific (TMO) Competitors

$595.30
-1.85 (-0.31%)
(As of 05/17/2024 ET)

TMO vs. AZN, NVS, ABT, ABBV, AMGN, PFE, ISRG, MRK, SNY, and ELV

Should you be buying Thermo Fisher Scientific stock or one of its competitors? The main competitors of Thermo Fisher Scientific include AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Intuitive Surgical (ISRG), Merck & Co., Inc. (MRK), Sanofi (SNY), and Elevance Health (ELV). These companies are all part of the "medical" sector.

Thermo Fisher Scientific vs.

Thermo Fisher Scientific (NYSE:TMO) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking.

Thermo Fisher Scientific presently has a consensus price target of $607.35, indicating a potential upside of 2.02%. AstraZeneca has a consensus price target of $81.00, indicating a potential upside of 5.33%. Given AstraZeneca's higher probable upside, analysts clearly believe AstraZeneca is more favorable than Thermo Fisher Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Thermo Fisher Scientific
0 Sell rating(s)
5 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.71
AstraZeneca
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

Thermo Fisher Scientific received 999 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 81.12% of users gave Thermo Fisher Scientific an outperform vote while only 58.06% of users gave AstraZeneca an outperform vote.

CompanyUnderperformOutperform
Thermo Fisher ScientificOutperform Votes
1053
81.12%
Underperform Votes
245
18.88%
AstraZenecaOutperform Votes
54
58.06%
Underperform Votes
39
41.94%

In the previous week, AstraZeneca had 9 more articles in the media than Thermo Fisher Scientific. MarketBeat recorded 24 mentions for AstraZeneca and 15 mentions for Thermo Fisher Scientific. Thermo Fisher Scientific's average media sentiment score of 1.17 beat AstraZeneca's score of 0.72 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Thermo Fisher Scientific
10 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AstraZeneca
12 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Thermo Fisher Scientific pays an annual dividend of $1.56 per share and has a dividend yield of 0.3%. AstraZeneca pays an annual dividend of $1.93 per share and has a dividend yield of 2.5%. Thermo Fisher Scientific pays out 10.0% of its earnings in the form of a dividend. AstraZeneca pays out 94.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 20.4% of AstraZeneca shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Thermo Fisher Scientific has higher earnings, but lower revenue than AstraZeneca. AstraZeneca is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$42.49B5.35$6.00B$15.5938.18
AstraZeneca$45.81B5.20$5.96B$2.0437.70

Thermo Fisher Scientific has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

Thermo Fisher Scientific has a net margin of 14.20% compared to AstraZeneca's net margin of 13.30%. AstraZeneca's return on equity of 30.42% beat Thermo Fisher Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Thermo Fisher Scientific14.20% 18.45% 8.65%
AstraZeneca 13.30%30.42%11.62%

Summary

Thermo Fisher Scientific beats AstraZeneca on 14 of the 20 factors compared between the two stocks.

Get Thermo Fisher Scientific News Delivered to You Automatically

Sign up to receive the latest news and ratings for TMO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TMO vs. The Competition

MetricThermo Fisher ScientificMeasuring & controlling devices IndustryMedical SectorNYSE Exchange
Market Cap$227.24B$20.46B$5.28B$18.11B
Dividend Yield0.26%3.41%43.85%3.44%
P/E Ratio38.1821.79128.7624.32
Price / Sales5.3522.452,365.5011.39
Price / Cash19.6015.2436.5319.45
Price / Book4.993.605.756.01
Net Income$6.00B$536.75M$108.64M$966.65M
7 Day Performance0.38%0.29%1.40%1.85%
1 Month Performance9.88%2.43%4.29%7.14%
1 Year Performance13.71%33.55%7.71%21.67%

Thermo Fisher Scientific Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
2.6054 of 5 stars
$77.04
-0.5%
$81.00
+5.1%
+2.9%$238.86B$45.81B37.7689,900Analyst Revision
NVS
Novartis
2.2497 of 5 stars
$103.31
+1.0%
$115.00
+11.3%
+1.3%$211.17B$47.73B13.9476,057
ABT
Abbott Laboratories
4.969 of 5 stars
$104.00
-0.7%
$121.50
+16.8%
-4.3%$180.92B$40.11B32.40114,000Insider Selling
Short Interest ↑
Positive News
ABBV
AbbVie
4.5606 of 5 stars
$161.55
+0.2%
$174.31
+7.9%
+16.1%$285.28B$54.32B47.9450,000Analyst Forecast
Short Interest ↑
Analyst Revision
AMGN
Amgen
4.7975 of 5 stars
$311.41
+1.0%
$305.65
-1.8%
+38.9%$167.05B$28.19B44.4926,700Options Volume
PFE
Pfizer
4.9967 of 5 stars
$28.35
-0.3%
$35.86
+26.5%
-22.1%$160.65B$58.50B-472.4288,000
ISRG
Intuitive Surgical
4.5958 of 5 stars
$384.19
+0.9%
$396.17
+3.1%
+29.4%$136.27B$7.12B69.3513,676Insider Selling
Short Interest ↑
MRK
Merck & Co., Inc.
4.6121 of 5 stars
$128.66
-0.5%
$131.33
+2.1%
+14.3%$325.87B$61.40B142.9672,000Analyst Revision
News Coverage
SNY
Sanofi
2.8595 of 5 stars
$49.50
-1.4%
$55.00
+11.1%
-9.3%$125.22B$46.61B24.8786,088Analyst Revision
ELV
Elevance Health
4.0428 of 5 stars
$534.63
-0.8%
$587.42
+9.9%
+19.1%$124.26B$171.34B20.21104,900Short Interest ↑
Positive News

Related Companies and Tools

This page (NYSE:TMO) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners